- Home
- CRDF vs BANX Comparison
CRDF vs BANX Comparison
Compare CRDF & BANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRDF | BANX |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.1M | 149.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CRDF | BANX |
|---|---|---|
| Price | $2.93 | $22.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.63 | N/A |
| AVG Volume (30 Days) | ★ 914.5K | 23.4K |
| Earning Date | 11-06-2025 | 06-17-2025 |
| Dividend Yield | N/A | ★ 9.66% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | $501,000.00 | ★ $29,467,794.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.88 |
| Revenue Growth | N/A | ★ 2.73 |
| 52 Week Low | $1.90 | $17.99 |
| 52 Week High | $5.00 | $21.67 |
Technical Indicators
Market Signals| Indicator | CRDF | BANX |
|---|---|---|
| Relative Strength Index (RSI) | 76.82 | 59.65 |
| Support Level | $2.32 | $22.06 |
| Resistance Level | $2.59 | $22.50 |
| Average True Range (ATR) | 0.15 | 0.33 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 99.34 | 87.92 |
Price Performance
Historical ComparisonAbout CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.